This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Analysis of effectiveness
It was not explicitly reported whether the analysis was conducted on an intention to treat basis. The primary health outcomes used were death and long-term morbidity assessed at ages 1 and 4 years. At 7 years (within 3 months of a child's seventh birthday), a developmental psychologist conducted standardised neurodevelopmental assessments. Six clinical areas were assessed (cognitive ability, neuromotor skills, general health, behaviour, hearing and vision) in terms of the degree of functional loss. According to the outcome of the assessment, children were characterised as normal, impaired, or mild, moderate or severely disabled. The overall status was defined according to the highest degree of impairment or disability in any of the six clinical areas. The particular instruments used to evaluate the outcomes and relevant definitions of impairment and functional disability are reported in the parent clinical study (United Kingdom Collaborative ECMO Trial Group 1996) .
The characteristics of the two groups were not discussed in the current paper. In addition, it was not reported whether the patient groups were comparable at analysis. Relevant details are provided in the parent clinical study (United Kingdom Collaborative ECMO Trial Group 1996) .
Effectiveness results
At 7 years of age the results were as follows.
The number of survivors with severe disability was 3 (3.2%) in the ECMO group and 0 (0%) in the CM group.
The number of survivors with moderate disability was 9 (9.7%) in the ECMO group and 6 (6.5%) in the CM group.
The number of survivors with mild disability was 13 (14.0%) in the ECMO group and 11(12.0%) in the CM group.
The number of survivors with impairment only was 21(22.6%) in the ECMO group and 15 (16.3%) in the CM group.
The number of survivors with no abnormal signs or disability was 10 (10.8%) in the ECMO group and 2 (2.2%) in the CM group.
The number of known survivors with no disability was 31 out of 56 (55.4%) in the ECMO group and 17 out of 34 (50.0%) in the CM group.
It was reported that ECMO was effective in reducing known death or severe disability at 7 years. There were 34 deaths (36.6%) in the ECMO group (n=93) and 54 deaths (58.7%) in the CM group (n=92). The difference in the number of deaths was statistically significant (relative risk 064, 95% confidence interval, CI: 0.47 to 0.86; p=0.004).
Clinical conclusions
At 7 years of age, neonatal ECMO was more effective in reducing deaths and increasing the number of survivors free 
Measure of benefits used in the economic analysis
The measures of benefit used were the life-years gained (LYG) and the disability-free LYG. The LYG were estimated by obtaining the date of death from respective health service providers. To estimate disability-free LYG, the authors estimated the period of survival for children whose status was not classified as mild, moderate or severely disabled. In addition, mean net benefits were also estimated for various willingness-to-pay threshold values for an additional lifeyear and for an additional disability-free life-year.
Direct costs
The health service costs included in the analysis were for initial hospitalisation and post-initial hospitalisation.
Initial hospitalisation covered the costs of a day on ECMO (inclusive of drugs, disposables, equipment, staff and overheads), a day on >90% oxygen, a day on a ventilator, supplementary oxygen at any concentration, the daily cost of standard neonatal care and the cost per ambulance journey.
Post-initial hospitalisation covered the costs of inpatient hospital readmission, an outpatient hospital visit (including paediatric visit, surgical visit, cardiology visit, accident and emergency visit, dietician visit, orthoptic visit, neurology visit and audiology visit), visit to a general practitioner, visit of health visitor and visits to other community carers (inclusive of paediatrician, community nurse, physiotherapist, occupational therapist, speech therapist, psychologist, counsellor, ophthalmologist, optometrist and dentist contact hour).
The analysis also included the cost of drugs prescribed by general practitioners and the cost of death (accounting for post-mortem examination and associated procedures, and transport of the deceased infant home by ambulance).
The cost and the quantities of resources used were reported separately in terms of summary costs (e.g. cost of a day on ECMO). The unit costs were based on actual data and were derived from published sources such as the British National Formulary. Where primary research was used to value resource use, the methods adopted were reported. The resource quantities were derived from actual data. Detailed resource use for hospital readmissions, outpatient hospital visits, and the use of community and other heath care services was estimated from telephone interviews with the parents (at 4, 8 and 12 months), contacts with general practitioners (at 4 and 7 years), and face-to-face interviews at the child's fourth and seventh birthday. Data obtained directly from the community health service providers were used in a final analysis. It was reported that the unit costs were combined with resource quantities to derive the net cost per child during the trial period. The costs were appropriately discounted and the price year was 2002/03.
Statistical analysis of costs
As data on resource items were missing for 18 children, simple linear regression and simulation-based multiple imputation were undertaken for each disability category. The costs were reported as means with standard deviations. Differences in the costs and resources used between the two groups were analysed using independent-sample t-tests, while differences in effects were analysed using the relative risk. Differences were assumed to be statistically significant if two-tailed p-values were </= 0.05. Non-parametric bootstrap estimation was employed in the derivation of 95% CIs for mean cost-differences. Because of skewed cost data, 1,000 bias-corrected bootstrap replications were used. In addition, non-parametric bootstrap simulation of the cost-effect pairs was conducted to derive 1,000 replications of each of the incremental cost-effectiveness ratios. This was represented graphically on 4-quadrant costeffectiveness planes. Mean net benefits and the 95% bootstrap CIs (i.e. defined as the willingness of the English NHS to pay for an additional life-year and for an additional disability-free life-year, multiplied by the difference of incremental effectiveness minus incremental cost) were estimated for different values of willingness-to-pay. Statistical analyses were undertaken using Microsoft Excel and SPSS software.
